|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Budesonide induces complete remission in autoimmune hepatitis显示文摘瞄准:泼尼松和 azathioprine 为自体免疫的肝炎(AIH ) 代表标准疗法。然而,仅仅, 65% 病人进入完全的组织学的宽恕。最近, budesonide (芽) 被报导是一种有希望的选择。在这研究,我们在 AIH 估计了芽的功效和安全。方法:十八个病人(12 个女人, 6 个男人;吝啬的年龄 45.4+/-21 年) 与芽(Budenofalk ) 与 AIH 被对待在上面三次每日、跟随的 3 mg 为至少 24 wk.Seven,病人们也有主要胆汁性肝硬变(n=5 ) 或主要致硬化的胆管炎(n=2 ) 的特征。先进的肝纤维变性或肝硬化在 6 个病人是在场的。结果:十五(83%) 病人们有完全的临床、生物化学的宽恕。十个病人,与尖锐肝炎包括五,作为首要的治疗被给芽,哪个七进入宽恕。三个病人,二与肝肝硬化,没改善。有第二线的治疗的所有病人经历了长期的宽恕。组织学的宽恕也在三个病人被看见。临床上相关的导致芽的副作用与肝肝硬化(n=4 ) 仅仅在病人被记录。结论:芽在在我们有 AIH.Side 效果的病人的多数的宽恕正式就职是有效的,治疗失败主要与肝肝硬化在病人被观察。 | Antal Csepregi Christoph R(o|¨)cken Gerhard Treiber Peter Malfertheiner | 2006 | World Journal of Gastroenterology2006，12，9： | 14 |
| 2 | Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis显示文摘AIM To assess the prevalence of a panel of serologic markers that reflect gut barrier dysfunction in a mixed cohort of pediatric and adult primary sclerosing cholangitis(PSC) patients.METHODS Sera of 67 PSC patients [median age(range): 32(5-79) years, concomitant IBD: 67% and cirrhosis: 20%] were assayed for the presence of antibodies against to F-actin(AAA Ig A/Ig G) and gliadin(AGA Ig A/Ig G)] and for serum level of intestinal fatty acid-binding protein(I-FABP) by ELISA. Markers of lipopolysaccharide(LPS) exposure [LPS binding protein(LBP)] and various antimicrobial antibodies [anti-OMP Plus Ig A and endotoxin core Ig A antibody(Endo CAb)] were also determined. Poor disease outcome was defined as orthotopic liver transplantation and/or liver-related death during the follow-up [median: 99(14-106) mo]. One hundred and fifty-three healthy subjects(HCONT) and 172 ulcerative colitis(UC) patients were the controls. RESULTS A total of 28.4%, 28.0%, 9% and 20.9% of PSC patients were positive for AAA Ig A, AAA Ig G, AGA Ig A and AGA Ig G, respectively. Frequencies of AAA Ig A and AAA Ig G(P < 0.001, for both) and AGA Ig G(P = 0.01, for both) but not AGA Ig A were significantly higher compared to both of the HCONT and the UC groups. In survival analysis, AAA Ig A-positivity was revealed as an independent predictor of poor disease outcome after adjusting either for the presence of cirrhosis [HR = 5.15(1.27-20.86), P = 0.022 or for the Mayo risk score(HR = 4.24(0.99-18.21), P = 0.052]. AAA Ig A-positivity was significantly associated with higher frequency of antimicrobial antibodies(P < 0.001 for Endo Cab Ig A and P = 0.012 for anti-OMP Plus Ig A) and higher level of the enterocyte damage marker(median I-FABP_(AAA Ig A pos vs neg): 365 vs 166 pg/m L, P = 0.011), but not with serum LBP level. CONCLUSION Presence of Ig A type AAA identified PSC patients with progressive disease. Moreover, it is associated with enhanced mucosal immune response to various microbial antigens and enterocyte damage further highlighting the importance of the gut-liver interaction in PSC. | Tamas Tornai Eszter Palyu Zsuzsanna Vitalis Istvan Tornai David Tornai Peter Antal-Szalmas Gary L Norman Zakera Shums Gabor Veres Antal Dezsofi Gabriella Par Alajos Par Peter Orosz Ferenc Szalay Peter Laszlo Lakatos Maria Papp | 2017 | World Journal of Gastroenterology2017，23，29： | 5 |
| 3 | Acute exacerbation of autoimmune hepatitis induced by Twinrix显示文摘We report on a 26-year-old man who presented with severe jaundice and elevated serum liver enzyme activities after having received a dose of Twinrix(○R). In his past medical history, jaundice or abnormal liver function tests were never recorded. Following admission, an elevated immunoglobulin G level and antinuclear antibodies at a titer of 320 with a homogenous pattern were found. Histology of a liver biopsy showed marked bridging liver fibrosis and a chronic inflammation, compatible with autoimmune hepatitis. Treatment was started with budesonide and ursodeoxycholic acid,and led to complete normalization of the pathological liver function tests. We believe that Twinrix(○R) led to an acute exacerbation of an unrecognized autoimmune hepatitis in our patient. The pathogenesis remains to be clarified. It is tempting to speculate that inactivated hepatitis A virus and/or recombinant surface antigen of the hepatitis B virus -as seen in patients with chronic hepatitis C and unrecognized autoimmune hepatitis who were treated with interferon alpha-might have been responsible for disease exacerbation. | Antal Csepregi Gerhard Treiber Christoph R(o|¨)cken Peter Malfertheiner | 2005 | World Journal of Gastroenterology2005，11，26： | 2 |
| 4 | Liquid chromatographic enantioseparation of spinlabelled β-amino acids显示文摘 | Antal Peter Roland Torok Karen Wright | 2003 | Journal of Chromatography A2003，1021，： | 1 |
| 5 | Diuretic actions in man of a selective kappa opioid agonist:U 62 066E 显示文摘 | Peters GR Ward NJ Antal EG | 1987 | 240(1) :128 -1311987，240，1： | 1 |
| 6 | Occurrence of thyroid autoimmunity in children with type 1 diabetes mellitus 显示文摘 | Anna K Peter T Antal D | 2008 | Hung Med J2008，2，： | 1 |
| 7 | Separation of Enantiomers and Control of Elution Order of β-Lactams by GC Using Cyclodextrin-Based Chiral Stationary Phases显示文摘 | Ke Huang Daniel W. Armstrong Eniko Forro Ferenc Fulop Antal Peter | 2009 | Chromatographia (-)2009，，3： | 1 |
| 8 | Pancreatic Autoantibodies and Autoantibodies Against Goblet Cells in Pediatric Patients With Inflammatory Bowel Disease显示文摘 | Marta Kovacs Peter Laszlo Lakatos Maria Papp Silvia Jacobsen Eva Nemes Marianne Polgar Eniko Solyom Piroska Bodi Agnes Horvath Katalin Eszter Muller Kriszta Molnar Doloresz Szabo Aron Cseh Antal Dezsofi Andras Arato Gabor Veres | 2012 | Journal of Pediatric Gastroenterology and Nutrition2012，，4： | 1 |
| 9 | Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease显示文摘AIM: To assess the prevalence and stability of different antiphospholipid antibodies(APLAs) and their association with disease phenotype and progression in inflammatory bowel diseases(IBD) patients.METHODS: About 458 consecutive patients [Crohn's disease(CD): 271 and ulcerative colitis(UC): 187] were enrolled into a follow-up cohort study in a tertiary IBD referral center in Hungary. Detailed clinical phenotypes were determined at enrollment by reviewing the patients' medical charts. Disease activity, medical treatment and data about evolvement of complications or surgical interventions were determined prospectively during the follow-up. Disease course(development f complicated disease phenotype and need for surgery),occurrence of thrombotic events, actual state of diseaseactivity according to clinical, laboratory and endoscopic scores and accurate treatment regime were recorded during the follow-up,(median, 57.4 and 61.6 mo for CD and UC). Sera of IBD patients and 103 healthy controls(HC) were tested on individual anti-β2-Glycoprotein-I(anti-β2-GPI IgA/M/G), anti-cardiolipin(ACA IgA/M/G)and anti-phosphatidylserine/prothrombin(anti-PS/PT IgA/M/G) antibodies and also anti-Saccharomyces cerevisiae antibodies(ASCA IgA/G) by enzyme-linked immunosorbent assay(ELISA). In a subgroup of CD(n = 198) and UC patients(n = 103), obtaining consecutive samples over various arbitrary timepoints during the disease course, we evaluated the intraindividual stability of the APLA status. Additionally,we provide an overview of studies, performed so far, in which significance of APLAs in IBD were assessed.RESULTS: Patients with CD had significantly higher prevalence of both ACA(23.4%) and anti-PS/PT(20.4%) antibodies than UC(4.8%, p < 0.0001 and10.2%, p = 0.004) and HC(2.9%, p < 0.0001 and15.5%, p = NS). No difference was found for the prevalence of anti-β2-GPI between different groups(7.2%-9.7%). In CD, no association was found between APLA and ASCA status of the patients.Occurrence of anti-β2-GPI, ACA and anti-PS/PT was not different between the group of patients with active vs inactive disease state according to appropriate clinical, laboratory and endoscopic scores in CD as well as in UC patients. All subtypes of anti-β2-GPI and ACA IgM status were found to be very stable over time, in contrast ACA IgG and even more ACA IgA status showed significant intraindividual changes.Changes in antibody status were more remarkable in CD than UC(ACA IgA: 49.9% vs 23.3% and ACA IgG:21.2% vs 5.8%). Interestingly, 59.1% and 30.1% of CD patients who received anti-TNF therapy showed significant negative to positive changes in ACA IgA and IgG antibody status respectively. APLA status was not associated with the clinical phenotype at diagnosis or during follow-up, medical therapy, or thrombotic events and it was not associated with the probability of developing complicated disease phenotype or surgery in a Kaplan-Meier analysis.CONCLUSION: The present study demonstrated enhanced formation of APLAs in CD patients. However,presence of different APLAs were not associated with the clinical phenotype or disease course. | Nora Sipeki Laszlo Davida Eszter Palyu Istvan Altorjay Jolan Harsfalvi Peter Antal Szalmas Zoltan Szabo Gabor Veres Zakera Shums Gary L Norman Peter L Lakatos Maria Papp | 2015 | World Journal of Gastroenterology2015，21，22： | 1 |
| 10 | Immune phenotype in children with therapy-nave remitted and relapsed Crohn’s disease显示文摘AIM: To characterize the prevalence of subpopulations of CD4+ cells along with that of major inhibitor or stimulator cell types in therapy-nave childhood Crohn's disease (CD) and to test whether abnormalities of immune phenotype are normalized with the improvement of clinical signs and symptoms of disease. METHODS: We enrolled 26 pediatric patients with CD. 14 therapy-nave CD children; of those, 10 children remitted on conventional therapy and formed the remission group. We also tested another group of 12 chil-dren who relapsed with conventional therapy and were given infliximab; and 15 healthy children who served as controls. The prevalence of Th1 and Th2, nave and memory, activated and regulatory T cells, along with the members of innate immunity such as natural killer (NK), NK-T, myeloid and plasmocytoid dendritic cells (DCs), monocytes and Toll-like receptor (TLR)-2 and TLR-4 expression were determined in peripheral blood samples. RESULTS: Children with therapy-nave CD and those in relapse showed a decrease in Th1 cell prevalence. Simultaneously, an increased prevalence of memory and activated lymphocytes along with that of DCs and monocytes was observed. In addition, the ratio of myeloid /plasmocytoid DCs and the prevalence of TLR-2 or TLR-4 positive DCs and monocytes were also higher in therapy-nave CD than in controls. The majority of alterations diminished in remitted CD irrespective of whether remission was obtained by conventional or biological therapy. CONCLUSION: The finding that immune phenotype is normalized in remission suggests a link between immune phenotype and disease activity in childhood CD. Our observations support the involvement of members of the adaptive and innate immune systems in childhood CD. | Aron Cseh Barna Vasarhelyi Kriszta Molnar Balazs Szalay Peter Svec Andras Treszl Antal Dezsofi Peter Laszlo Lakatos Andras Arato Tivadar Tulassay Gabor Veres | 2010 | World Journal of Gastroenterology2010，16，47： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员